» Articles » PMID: 22414705

Noradrenergic Moderation of Working Memory Impairments in Adults with Autism Spectrum Disorder

Overview
Specialties Neurology
Psychology
Date 2012 Mar 15
PMID 22414705
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

In addition to having difficulties with social communications, individuals with an autism spectrum disorder (ASD) often also experience impairment in higher-order, executive skills. The present study examined the effects of pharmacological modulation of the norepinephrine system on the severity of such impairments. A sample of 14 high-functioning adults with ASD and a demographically-matched comparison group of 13 typically developing individuals participated. An AX continuous performance test (AX-CPT) was used to evaluate working memory and inhibitory control. AX-CPT performance was assessed following administration of a single dose of propranolol (a beta adrenergic antagonist) and following placebo (sugar pill) administration. Individuals with ASD performed more poorly than non-ASD individuals in the working memory condition (BX trials). Importantly, administration of propranolol attenuated this impairment, with the ASD group performing significantly better in the propranolol condition than the placebo condition. Working memory performance of the non-ASD group was unaffected by propranolol/placebo administration. No group or medication effects were observed for the inhibition condition (AY trials). The present findings suggest that norepinephrine may play a role in some, but not necessarily all, cognitive impairments associated with ASD. Additional research is needed to fully understand whether this role is primarily causal or compensatory in nature.

Citing Articles

Noradrenergic and Dopaminergic modulation of meta-cognition and meta-control.

Ershadmanesh S, Rajabi S, Rostami R, Moran R, Dayan P PLoS Comput Biol. 2025; 21(2):e1012675.

PMID: 40009609 PMC: 11903042. DOI: 10.1371/journal.pcbi.1012675.


The Anti-Apoptotic Effect of Ranolazine on Cerebral Protection during Cardiopulmonary Bypass and Carotid Artery Surgery.

Akgul E, Gunduz M, Parlar A, Guner Y, Eroglu M, Ozhan A Acta Cardiol Sin. 2024; 40(1):77-86.

PMID: 38264074 PMC: 10801430. DOI: 10.6515/ACS.202401_40(1).20230814C.


A Pilot Feasibility Study Assessing the Combined Effects of Early Behavioral Intervention and Propranolol on Autism Spectrum Disorder (ASD).

Hirst K, Zamzow R, Stichter J, Beversdorf D Children (Basel). 2023; 10(10).

PMID: 37892301 PMC: 10605265. DOI: 10.3390/children10101639.


Catecholaminergic and cholinergic neuromodulation in autism spectrum disorder: A comparison to attention-deficit hyperactivity disorder.

Koevoet D, Deschamps P, Kenemans J Front Neurosci. 2023; 16:1078586.

PMID: 36685234 PMC: 9853424. DOI: 10.3389/fnins.2022.1078586.


Propranolol versus Other Selected Drugs in the Treatment of Various Types of Anxiety or Stress, with Particular Reference to Stage Fright and Post-Traumatic Stress Disorder.

Szeleszczuk L, Fraczkowski D Int J Mol Sci. 2022; 23(17).

PMID: 36077489 PMC: 9456064. DOI: 10.3390/ijms231710099.